secwatch.observer — SEC 8-K summary
======================================

Issuer:     BICYCLE THERAPEUTICS PLC (BCYC)
CIK:        0001761612
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001104659-23-087020
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicycle Therapeutics Q2 net loss widens to $1.41/sh; cash >$600M after $230M raise
--------------------------------------------------------------------------------

- Net loss $42.6M ($1.41 loss per share) vs $26.8M ($0.90) a year ago; R&D expense doubled to $39.7M.
- Cash $340.4M at June 30, 2023; pro-forma over $600M including $230M July offering and $45M Bayer upfront.
- Strategic collaborations with Novartis (up to $1.7B milestones) and Bayer (up to $1.7B) for Bicycle radio-conjugates.
- Appointed Alethia Young as CFO effective July 17, 2023; clinical updates on BT8009 expected in 2H23.
- Preclinical data for Pb-BCY20603 BRC showed complete tumor regressions in rodent xenograft studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761612/000110465923087020/0001104659-23-087020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761612/000110465923087020/tm2322663d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-087020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer